Johnson & Johnson Vision

Johnson & Johnson to Participate in the Barclays 26th Annual Global Healthcare Conference

Retrieved on: 
Wednesday, February 14, 2024
Medical Devices, Medical Supplies, Fitness & Nutrition, Health Technology, Biotechnology, Other Health, Health, Pharmaceutical, General Health, Eastern Time Zone, Johnson & Johnson, Barclays, Johnson & Johnson Vision, Conference, Webcast, JNJ

Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at the Loews Miami Beach Hotel, Miami Beach, FL.

Key Points: 
  • Johnson & Johnson (NYSE: JNJ) will participate in the Barclays 26th Annual Global Healthcare Conference on Wednesday, March 13th, at the Loews Miami Beach Hotel, Miami Beach, FL.
  • Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision will represent the Company in a session scheduled at 10:45 a.m. (Eastern Time).
  • The audio webcast replay will be available approximately 48-hrs after the webcast.
  • View source version on businesswire.com: https://www.businesswire.com/news/home/20240214565598/en/

Centricity Vision Announces CEO Transition: Leonard Borrmann to Succeed Rob Thornhill as Chief Executive Officer

Retrieved on: 
Wednesday, December 20, 2023
Johnson & Johnson Vision, Centricity, Business, Marketing, Surgeon, Business development, Growth, Patient, Head, Clinical research, AMO, Management

CARLSBAD, Calif., Dec. 20, 2023 /PRNewswire/ -- Centricity Vision Inc., a global, commercial-stage ophthalmic technology company, today named Leonard Borrmann as the company's new Chief Executive Officer (CEO), effective immediately.

Key Points: 
  • CARLSBAD, Calif., Dec. 20, 2023 /PRNewswire/ -- Centricity Vision Inc., a global, commercial-stage ophthalmic technology company, today named Leonard Borrmann as the company's new Chief Executive Officer (CEO), effective immediately.
  • Mr. Thornhill served as CEO of Centricity Vision since 2019, transforming the company, the management team, and the ZEPTO® technology to achieve surgical and clinical excellence.
  • Borrmann joined Centricity Vision in 2021, managing new product development and spearheading the development of the ZeptoLink IOL Positioning System™ from concept to commercial launch in record time.
  • "I am honored to succeed Rob, and want to thank him for his substantial contributions to the company," said Leonard Borrmann.

Bausch + Lomb Will Present New Scientific Data and Analyses at American Academy of Optometry Annual Meeting

Retrieved on: 
Wednesday, October 4, 2023
Health, General Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Contact, Ernest, Cerebral edema, Palace, Employment, Pain, Telecanthus, Incidence, Hilton New Orleans Riverside, Steroid, Viral, Macular edema, Herpes simplex, NYSE, Chickenpox, Magazine Street, Canal Street, Conjunctiva, EYE, Tchoupitoulas Street, Risk, Pigment, Intraocular pressure, SM, Optic nerve, FDA, INA War Museum, Iris, Andhra Pradesh Decentralisation and Inclusive Development of All Regions Act, 2020, Fungal infection, Poydras Street, Sclera, Eye, Bausch, History, Slit lamp, Glaucoma, Ocular hypertension, DED, Cornea, IOP, Contact lens, Infection, American Academy, Inflammation, Johnson & Johnson Vision, Vaccinia, Bausch & Lomb, Lens (vertebrate anatomy), Visual acuity, Pharmaceutical industry, Medical device, Hospital, Telescopic sight, Hotel, Gasoline, Nursing, Dietary supplement, Vaccine, Blinking, O.D, Patient

Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.

Key Points: 
  • Bausch + Lomb acquired the Blink brand of eye drops for dry eyes and contacts from Johnson & Johnson Vision earlier this year.
  • Another educational event will highlight practical patient cases using products from across the company’s consumer, vision care and pharmaceutical portfolios.
  • The Bausch + Lomb schedule at AAOpt:
    “Clinical Dry Eye Findings in Patients Using a Novel Lipid-Containing Eye Drop.” Joshi et al.
  • “Perfluorohexyloctane, an Eye Drop for Dry Eye Disease, Reduces Corneal Staining Across All Regions of the Cornea.” Fahmy et al.

Johnson & Johnson Vision announces launch of ELITA™ Platform to Correct Myopia with New SILK Procedure at the European Society of Cataract and Refractive Surgeons Congress

Retrieved on: 
Wednesday, August 30, 2023
Presbyopia, Johnson & Johnson Vision, Natural Resources, A4, Patient, Near-sightedness, Congress, Environment, Johnson, Element, EDOF, Small incision lenticule extraction, Ophthalmology, Cataract, Woman, Symposia, Abstract, The New Elite, Eye, Carbon, Lock (computer science), Intraocular lens, Cornea, Surgeon, SILK, Food, IIS, Recycling, Toronto Congress Centre, Astigmatism, European Society of Clinical Microbiology and Infectious Diseases, Health, Dentistry, Telescopic sight, Pharmaceutical industry, Software

LONDON, Aug. 30, 2023 /PRNewswire/ -- Johnson & Johnson Vision*, a global leader in eye health and part of Johnson & Johnson MedTechi, will announce the launch of a next-generation laser vision correction solution, the ELITATM Platform, at the 41st European Society of Cataract and Refractive Surgeons (ESCRS) congress, 8-12 September 2023. The congress will also showcase a range of breakthrough data, with over 30 abstracts supported by Johnson & Johnson Vision accepted for presentation.

Key Points: 
  • The congress will also showcase a range of breakthrough data, with over 30 abstracts supported by Johnson & Johnson Vision accepted for presentation.
  • The ELITATM Platform enables surgeons to perform refractive correction on patients with myopia, with or without astigmatism, using the new SILK (Smooth Incision Lenticule Keratomileusis) procedure.
  • The Johnson & Johnson Vision ESCRS Booth (#B202) will have live demonstration areas for surgeons to experience first-hand the ELITATM Femtosecond Laser as well as other leading Johnson & Johnson Vision products.
  • Additionally, attendees will be able to participate in the Toric VR Simulator experience alongside dry labs and meet the expert sessions at the booth and in the Johnson & Johnson Vision Lighthouse.

Global Medical Loupes Research Report 2032-2031: Zooming In on Growth - Market Set to Surge with Advancing Technology - ResearchAndMarkets.com

Retrieved on: 
Wednesday, August 9, 2023
General Health, Health, Medical Supplies, Medical Devices, Dentistry, Maintenance, Medicine, Surgeon, United Nations, Prevalence, 3D, Lens, Ageing, Research, LED, Journal, Acquisition, Neurosurgery, United, Risk, Ophthalmology, Johnson & Johnson Vision, Conditional sentence, Growth, Peter Hancock (professor), 3D printing, Camera, Health care, Medical device, Retail, Marketing

In the ever-evolving medical industry, the medical loupes market stands out as a burgeoning sector, dedicated to enhancing surgical precision and accuracy.

Key Points: 
  • In the ever-evolving medical industry, the medical loupes market stands out as a burgeoning sector, dedicated to enhancing surgical precision and accuracy.
  • The rising demand for minimally invasive surgeries is expected to drive the growth of the medical loupes market in the coming years.
  • The global medical loupes market is highly competitive, with several key players operating in the market.
  • Who are the key competitors and what are their key strategies to enhance their market presence in the Medical Loupes market worldwide?

Bausch + Lomb Solidifies Leadership Team

Retrieved on: 
Tuesday, August 1, 2023
Retail, Health, Other Retail, Specialty, General Health, Pharmaceutical, Optical, Boston Consulting Group, Partnership, Inovio Pharmaceuticals, Bausch & Lomb, PwC, Allergan, Bausch, Waterhouse, Johnson & Johnson Vision, Privacy, Merck, Digital, Merrill (company), NYSE, Management, Saunders

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its executive leadership team including the creation of two new roles.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced changes to its executive leadership team including the creation of two new roles.
  • The moves build on a reshuffling announced in early June after Chairman and CEO Brent Saunders, who previously served as CEO from 2010 to 2013, rejoined Bausch + Lomb.
  • “Seizing the opportunity in front of us means acting swiftly, which is why I’ve been so focused on establishing a refreshed leadership team,” said Saunders.
  • Gevgilili is currently chief human resources officer at INOVIO Pharmaceuticals and previously held human resources leadership roles at Allergan, Merck and Merrill Lynch.

Hyperfine, Inc. Announces Promotion of Tom Teisseyre, Ph.D. to Chief Operating Officer

Retrieved on: 
Tuesday, July 18, 2023
Health Technology, Health, Neurology, Medical Devices, Pascal Photocoagulator, San Francisco, University of California, Berkeley, Georgia Tech, Doctor of Philosophy, University of California, San Francisco, Johnson & Johnson Vision, Multimedia, Biomedical engineering, Bill & Melinda Gates Foundation, Publication, UC, Verily, Bill, FDA, Hyperfine structure, Medical device, Management

Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced the promotion of Tom Teisseyre, Ph.D. to chief operating officer.

Key Points: 
  • Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the Swoop® system, the world’s first FDA-cleared portable magnetic resonance brain imaging system, today announced the promotion of Tom Teisseyre, Ph.D. to chief operating officer.
  • View the full release here: https://www.businesswire.com/news/home/20230718631231/en/
    Dr. Teisseyre has served as chief product officer since June 2021 and has extensive prior experience in medical devices and imaging.
  • Hyperfine, Inc. also announced that, for personal reasons, Khan Siddiqui, M.D., will transition from full-time to part-time as chief medical officer and chief strategy officer.
  • “I am excited to welcome Tom into his expanded role as chief operating officer.

Tactile Medical Appoints Sherri Ferstler as Senior Vice President of Sales

Retrieved on: 
Tuesday, July 18, 2023
Contact, State University of New York College of Environmental Science and Forestry, Senior, State university system, History, Johnson & Johnson Vision, TCMD, Urology, Pfizer, Endo International, Pharmaceutical industry, Management, Psychology, Buffalo

MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Sherri Ferstler to the position of Senior Vice President of Sales, effective July 31, 2023.

Key Points: 
  • MINNEAPOLIS, July 18, 2023 (GLOBE NEWSWIRE) -- Tactile Systems Technology, Inc. (“Tactile Medical”) (Nasdaq: TCMD), a medical technology company providing therapies for people with chronic disorders, today announced the appointment of Sherri Ferstler to the position of Senior Vice President of Sales, effective July 31, 2023.
  • “Sherri brings extensive executive sales leadership experience, most recently within Johnson & Johnson Vision, where she led a team of over 325.
  • Adding Sherri further enriches our executive leadership team, our ability to build and operate at scale, and our ability to lead change and expand productivity.”
    Prior to joining Tactile Medical, Ms. Ferstler served as Vice President Sales, North America for Johnson & Johnson Vision since 2016.
  • Ms. Ferstler began her career in 1992 with Parke-Davis Pharmaceuticals where she served in a variety of sales, sales management and training and development roles.

Bausch + Lomb Expands OTC Product Line with Acquisition of Blink® Eye Drops

Retrieved on: 
Thursday, July 6, 2023
Medical Devices, Health, Pharmaceutical, Optical, Medical Supplies, Consumer, OTC, Bausch & Lomb, Eye, Incidence, United, Dry, Acquisition, NYSE, Johnson & Johnson Vision, Telescopic sight, Blinking

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has purchased the Blink® product line of eye and contact lens drops from Johnson & Johnson Vision.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced an affiliate has purchased the Blink® product line of eye and contact lens drops from Johnson & Johnson Vision.
  • * The strategic acquisition is the latest example of the company’s commitment to increasing over-the-counter (OTC) consumer convenience in eye care.
  • “There’s a growing need for relieving the symptoms of dry eyes and dry contact lenses, and OTC products are often the first option consumers choose,” said John Ferris, executive vice president, Consumer, Bausch + Lomb.
  • “The addition of Blink expands our robust portfolio of OTC eye care brands, enabling us to provide more choices for consumers and eye care professionals.”
    According to a 2022 Gallup Study, 57% of American adults report suffering from eye dryness, and of them, nearly half (48%) use OTC lubricant drops to obtain relief.

The Ophthalmology Foundation Elects Two New Board Members

Retrieved on: 
Thursday, June 29, 2023
Bachelor, BS, University, Viatris, Teaching, Epidemiology, Medicine, Stony Brook University, Research, Johnson & Johnson Vision, Ophthalmology, Walden University, The Fred Hollows Foundation, Public health, SAN, Knowledge, Johnson & Johnson, Management, Finance, Biology

SAN FRANCISCO, June 29, 2023 /PRNewswire-PRWeb/ -- The Ophthalmology Foundation is pleased to announce the election of two new members, Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision, and Dr. Jeffrey Nau, President of the Eye Care Division at Viatris Inc., to its Board of Directors. As distinguished leaders within the global health sector, Mr. Menziuso and Dr. Nau will be invaluable in helping the organization deliver upon its mission to improve eye care and advance the preservation and restoration of vision.

Key Points: 
  • The Ophthalmology Foundation has elected Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision, and Dr. Jeffrey Nau, President of the Eye Care Division at Viatris Inc., to its Board of Directors.
  • SAN FRANCISCO, June 29, 2023 /PRNewswire-PRWeb/ -- The Ophthalmology Foundation is pleased to announce the election of two new members, Peter Menziuso, Company Group Chairman, Johnson & Johnson Vision, and Dr. Jeffrey Nau, President of the Eye Care Division at Viatris Inc., to its Board of Directors.
  • With their combined skills, and commitment, Board members provide the knowledge, expertise, and leadership necessary to advise the organization and provide resources to ensure its continued success.
  • "Since our founding, the Ophthalmology Foundation has been committed to improving global eye care and ophthalmic practice within low-resource and underserved countries," said David Pyott, MDhc, President of the Foundation's Board of Directors.